undamentalytics Newsletter
Sign in

Keros Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Keros Therapeutics, Inc. had total assets of $338m, total liabilities of $34.9m and shareholders' equity of $303m. It held $287m in cash against $0 of debt: net cash of $287m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents7266230279331560287258
Receivables—01800340
Total current assets9268251286347589315267
Total assets11269255307370616338288
Accounts payable22435522
Deferred revenue (current)—————0——
Total current liabilities47121724272012
Total debt00000000
Total liabilities108122938443525
Shareholders' equity−19262243277332572303262
Non-controlling interests and other (assets − liabilities − equity)20———————
Net debt (negative = net cash)−7−266−230−279−331−560−287−258
Shares outstanding2m—24m28m32m41m39m—

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ALEC vs KROSKROS vs LCTXKROS vs PRQR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Keros Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Keros Therapeutics, Inc.